LENZ Therapeutics (LENZ) Assets Average (2021 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Assets Average of $289.2 million for Q1 2026, up 38.86% year-over-year from $208.3 million in Q1 2025, and up 11.97% quarter-over-quarter from $258.3 million in Q4 2025.
LENZ Therapeutics (LENZ) Assets Average (2021 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Assets Average for 6 consecutive years, with $289.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 38.86% year-over-year to $289.2 million; the TTM figure through Mar 2026 stood at $289.2 million (up 38.86% YoY), while the FY2025 annual figure was $260.6 million, up 82.43% from the prior year.
- Assets Average grew to $289.2 million in Q1 2026 per LENZ's latest filing, from $258.3 million in the prior quarter.
- Across five years, Assets Average topped out at $390.3 million in Q1 2022 and bottomed at $143.8 million in Q1 2024.
- Historically, Assets Average has averaged $262.0 million across 5 years, with a median of $258.3 million in 2025.
- Annual changes were most pronounced in 2024 — Assets Average sank 54.47% — and 2025, when it soared 44.79%.
- LENZ Therapeutics' Assets Average stood at $328.4 million in 2022, then tumbled by 48.75% to $168.3 million in 2023, then soared by 30.51% to $219.7 million in 2024, then gained by 17.59% to $258.3 million in 2025, then climbed by 11.97% to $289.2 million in 2026.
- Business Quant data shows LENZ's Assets Average at $289.2 million in Q1 2026, $258.3 million in Q4 2025, and $214.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | 254.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 254.57 Mn |
| Mar 31, 2026 | 289.21 Mn |
| Dec 31, 2025 | 258.29 Mn |
| Sep 30, 2025 | 214.02 Mn |
| Jun 30, 2025 | 209.29 Mn |
| Mar 31, 2025 | 208.28 Mn |
| Dec 31, 2024 | 219.66 Mn |
| Sep 30, 2024 | 213.32 Mn |
| Jun 30, 2024 | 209.98 Mn |
| Mar 31, 2024 | 143.85 Mn |
| Dec 31, 2023 | 168.30 Mn |
| Sep 30, 2023 | 276.64 Mn |
| Jun 30, 2023 | 298.52 Mn |
| Mar 31, 2023 | 315.95 Mn |
| Dec 31, 2022 | 328.37 Mn |
| Sep 30, 2022 | 344.32 Mn |
| Jun 30, 2022 | 366.20 Mn |
| Mar 31, 2022 | 390.30 Mn |
| Dec 31, 2021 | 409.07 Mn |
| Sep 30, 2021 | 401.63 Mn |